Search Within

Gastrointestinal Oncology Service

Formats
  1. Journal Article (2350)
  2. Meeting Abstract (1870)
  3. Review (150)
  4. Book Section (127)
  5. Editorial (100)
  6. Guidelines (39)
  7. Correspondence (34)
  8. Conference Paper (24)
  9. Miscellaneous (23)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Solid Tumor Oncology Division (4746)
  2. Department of Medicine (4744)
  3. Center for Pancreatic Cancer Research (2313)
  4. Surgery (1066)
  5. Survivorship Research (1014)
  6. Epidemiology and Biostatistics (842)

More Groups

People
  1. Eileen O'Reilly (803)
  2. Leonard Saltz (796)
  3. Ghassan Abou-Alfa (583)
  4. Nancy Kemeny (545)
  5. David Kelsen (538)
  6. David Ilson (443)

More People

Years
  1. 2025 (221)
  2. 2024 (309)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1290)
  2. Annals of Oncology (331)
  3. Annals of Surgical Oncology (148)
  4. Cancer (128)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1379)
  2. Oxford University Press (462)
  3. Elsevier Inc. (408)
  4. Springer (321)
  5. American Association for Cancer Research (281)
  6. Wiley Blackwell (241)

More Publishers

Results (4746)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase III, international, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P plus G) versus gemcitabine (G) for resected pancreatic cancer (APACT): Recurrence patterns
    Meeting Abstract

    Sahai, V.; Tabernero, J.; Van Cutsem, E.; Reni, M.; Tempero, M. A.; O'Reilly, E. M.; Berlin, J.; Riess, H.; Goldstein, D.; Li, M.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • How to improve toxicity evaluation in clinical trials? Testing new metrics from irinotecan or oxaliplatin-based treatments in metastatic colorectal cancer (mCRC): A pooled analysis from 2,349 patients in ARCAD database
    Meeting Abstract

    Tournigand, C.; Lopes, G.; Olswold, C. L.; Adams, R.; Zalcberg, J. R.; Van Cutsem, E.; Saltz, L. B.; Goldberg, R. M.; Hurwitz, H.; Bokemeyer, C.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC)
    Meeting Abstract

    Oh, D. Y.; Ajani, J. A.; Bang, Y. J.; Chung, H. C.; Lacy, J.; Lee, J.; Macarulla, T.; Manji, G. A.; O'Reilly, E. M.; Allen, S.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Receipt and survival outcomes by age following second-line therapy for metastatic CRC (mCRC): Analysis of 5,289 patients from the ARCAD Clinical Trials Program
    Meeting Abstract

    McCleary, N. J.; Harmsen, W. S.; VanCutsem, E.; Sobrero, A. F.; Goldberg, R. M.; Tabernero, J.; Seymour, M.; Saltz, L. B.; Giantonio, B. J.; Dirk, A.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Pancreatic ductal adenocarcinoma (PDAC), BRCA: Detailed analysis and outcomes of cohort from Memorial Sloan Kettering Cancer Center (MSK)
    Meeting Abstract

    Momtaz, P.; O'Connor, C. A.; Chou, J. F.; Capanu, M.; Yu, K. H.; Varghese, A. M.; Park, W.; Zervoudakis, A.; Li, J.; Ku, G. Y.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Impact of prior irinotecan exposure on outcomes of metastatic pancreatic cancer (mPC) patients
    Meeting Abstract

    O'Reilly, E. M.; Surinach, A.; Dillon, A.; Cockrum, P.; Yu, K. H.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Real-world patterns of care among patients with metastatic pancreatic cancer (mPC)
    Meeting Abstract

    O'Reilly, E. M.; Surinach, A.; Wu, Z.; Cockrum, P.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A randomized, multicenter, phase II trial of gemcitabine (G), cisplatin (C) plus /- veliparib (V) in patients with pancreas adenocarcinoma (PDAC) and a known germline (g)BRCA/ PALB2 mutation
    Meeting Abstract

    O'Reilly, E. M.; Lee, J. W.; Zalupski, M.; Capanu, M.; Park, J.; Golan, T.; Tahover, E.; Lowery, M. A.; Chou, J. F.; Sahai, V.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma
    Meeting Abstract

    Ly, M.; Molena, D.; Sihag, S.; Wu, A. J. C.; Shah, P. M.; Gu, P.; Sugarman, R.; Maron, S. B.; Chalasani, S. B.; Shcherba, M.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Early progression (progr) in patients (pts) with metastatic pancreatic cancer (mPaC) and a germline BRCA mutation (gBRCAm): Phase III POLO trial of olaparib (O) versus placebo (P)
    Meeting Abstract

    Macarulla, T.; Kindler, H. L.; Hammel, P.; Reni, M.; Van Cutsem, E.; Hall, M. J.; Park, J. O.; Hochhauser, D.; Arnold, D.; Oh, D. Y.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save